Clinical and pathological characteristics of Cuban patients with gastrointestinal stromal tumors in non-metastatic stages
Keywords:
GIST; non-metastatic stages, GIST, non-metastatic stagesAbstract
Introduction : Gastrointestinal stromal tumors are rare mesenchymal neoplasms, accounting for 0.2 % of all gastrointestinal tumors.
Objective : To characterize patients with Gastrointestinal stromal tumors in non-metastatic stages from the clinical and anatomopathological point of view.
Methods : Longitudinal and retrospective study, with 144 patients diagnosed with primary and located gastrointestinal stromal tumors, who were initially surgically intervented, and attended at the Hermanos Ameijeiras Hospital, between June 2003 and December 2016.
Results : The average age was 57 years. Male patients predominated, and abdominal pain, as the main form of presentation, while the most frequent location was the stomach, followed by the small intestine, and the mean tumor size was 10.3 cm. More than 75 % of patients had tumors larger than 5 cm, and more than 60 % of patients had a mitotic index ≤5, and 80 % had an intermediate or high risk (Fletcher criteria). The most frequent form of presentation was bleeding in colon/rectum tumors (50.0 %) and stomach (48.6 %), while abdominal pain was for the gastrointestinal stromal tumors of small intestine (47.5 %) and peritoneum (85.7 %). Complete surgical resection was achieved in 90 % of the cases. Nine patients, experienced progression of the disease. Fourteen patients developed metastases after surgery (9.7 %), and the most frequent location was the liver (92.8 %).
Conclusions : This is the first epidemiological report on gastrointestinal stromal tumors in Cuba, which provides a detailed information on the behavior of this disease in the so-called "real world", based on a centralized protocolization experience.
Downloads
References
Medrano R, Kinakú N, Rodriguez J. Factores pronósticos de recurrencia y supervivencia en tumores del estroma gastrointestinal. Gac Mex Oncol. 2015;14:259-67.
Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-69.
Giuliano K, Nagarajan N, Canner J. Gastric and small intestine gastrointestinal stromal tumors: do outcomes differ? J Surg Oncol. 2017;115:351-7. PubMed:PMID:27885685.
Hua Y, Hua X, Qi Z. Prognostic role ok the primary tumor site in patients with operable small intestine and gastrointestinal stromal tumors: a large population-based analysis. Oncotarget. 2017;9:8147-54. PubMed:PMID:29487722.
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-8.
Zhou J, Yan T, Huang Z. Clinical features and prognosis of gastrointestinal stromal tumors. Int J Clin Exp Med. 2016; 9:16367-72.
Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu R. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39-46. PubMed:PMID:26618334.
Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3-14. PubMed:PMID: 26276366.
Nishida T, Goto O, Raut CP, Yahagi N. Diagnostic and treatment strategy for small gastrointestinal stromal tumors. Cancer. 2016;122:3110-18. PubMed:PMID:27478963.
Nishida T, Tsujimoto M, Takahashi T, Hirota S, Blay JY, Wataya-Kaneda M. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. J Gastroenterol. 2016;51:571-8. PubMed:PMID:26511941.
Lima M, Soriano JL, Batista N. Sarcomas del estroma gastrointestinal (GIST). En: Manual de Prácticas Médicas. 4ta ed. La Habana: Editorial de Ciencias Médicas; 2012. p.682-98.
Grace L, James D, Martinez M. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015;24:298-302. PubMed:PMID:25277795.
Jiehua L, Haitian Z, Zhibai C. Clinico-pathological characteristics and prognostic factors ok gastrointestinal stromal tumors. Int J Clin Exp Pathol. 2015;8:15969-76. PubMed:PMID:26884871.
Bülbül Doğusoy G. Gastrointestinal stromal tumors: a multicenter study of 1160 Turkish cases. Turk J Gastroenterol. 2012;23:203-11.
Brady West D, Blake G. Clinicopathological features and outcome of gastrointestinal stromal tumors in an Afro-Caribbean population. J Natl Med Assoc. 2015;104:72-7.
Bhalgami R, Manish K, Patil P, Mehta S, Mohandas KM. Clinicopathological study of 113 gastrointestinal stromal tumors. Indian J Gastroenterol. 2013;32:22-7.
Sapalidis K, Panteli N, Strati T, Anastasiadis I, Kanellos I. Surgical management of gastrointestinal stromal tumors: a single centre's experience. Hippokratia. 2015;19:73-5. PubMed:PMID:26435652.
Arolfo S, Teggia PM, Nano M. Gastrointestinal stromal tumors: thirty years' experience of an Institution. World J Gastroenterol. 2013;17:1836-9.
Wang M, Xu J, Zhang Y, Tu L, Qiu WQ, Wang CJ. Gastrointestinal stromal tumor: 15-years' experience in a single center. BMC Surg. 2014;14:ID4277251.
Dip Borunda AK, Pimentel Renteria A, Pluma Jiménez M, Pérez Martínez M, Martínez Martínez G, Rivera Rivera S. Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico. J Gastrointest Oncol. 2016;7:632-7. PubMed:PMID:27563455.
Kindblom LG, Meis-Kindblom J, Bumming P, Dimitrijevic S, Miret M, Dortok A. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST). A population-based study of 600 cases. Ann Oncol. 2002;13(Suppl 5):s157-64.
Carrillo R, Candia A, Rodriguez Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol. 1997;28:160-5.
Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ. Prognostic value of Ki 67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol. 2014;7:2298-304.
Lu C, Liu L, Wu X, Xu W. CD133 and Ki-67 expression is associated with gastrointestinal stromal tumor prognosis. Oncol Lett. 2013;6:1289-94.
Bejarano Glez-Serna D, González Benjumea P, Rodríguez Padilla AR, Balongo García R. Tumores del estroma gastrointestinal. Revisión de nuestra experiencia. Rev Chil Cir. 2014;67:386-92.
McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012;215:53-9.
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411-9.
Sugase T, Takahashi T, Nakajima K. Clinicopathological characteristics surgery and survival outcomes of patients with gastrointestinal stromal tumors. Digestion. 2016;94:30-6.
Zhi X, Jiang B, Yu J, Røe OD, Qin J, Ni Q. Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:21541-8. PubMed:PMID:26891953.
Al-Kalaawy M, El-Zohairy MA, Mostafa A, Al-Kalaawy A, El-Sebae H. Gastrointestinal stromal tumors (GISTs), 10-year experience: Patterns of failure and prognostic factors for survival of 127 patients. J Egyp Nat Cancer Inst. 2012;24:31-9.
Jason K, Lopez N. Optimizing surgical and imatinib therapy of the treatment of gastrointestinal stromal tumors. J Gastrointest Surg. 2013;17:1997-2006.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
